Komori
Governance4568DAIICHI SANKYO COMPANY,LIMITEDPharmaceuticals

Notice of the Continuation of the Trust-Based Share Grant Program for Officers and Employees of Our U.S. Subsidiary

We plan to continue the trust-based share grant plan already introduced for officers and employees of our U.S. subsidiaries and extend the term of the trust agreement through the end of August 2029. In fiscal 2027 and fiscal 2028, we plan to acquire a total of approximately USD 285 million worth of the Company’s shares.

Worth reading
—
Scored from 0 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
285
USD millions (approximately USD 145 million in fiscal 2027 and USD 140 million in fiscal 2028)
Wording
Conditional
How definitive the wording is.

Contents of this filing

Changes this time

We plan to continue the trust-based share grant plan already introduced, amend the trust agreement as of 3 August 2026, and extend the trust period through the end of August 2029. We plan to acquire shares in fiscal 2027 and fiscal 2028.

この書類は、機関設計や取締役会の構成そのものは述べていません。上に示したのは、この書類が述べている変更点です。

Contents of this filing
ItemDetails
Changes this timeWe plan to continue the trust-based share grant plan already introduced, amend the trust agreement as of 3 August 2026, and extend the trust period through the end of August 2029. We plan to acquire shares in fiscal 2027 and fiscal 2028.
Items this document does not state (7)
Corporate Governance StructureNumber of directorsNumber of independent officersCommitteePolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To enhance the engagement of officers and employees and attract and retain talented personnel.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Continuation of the Trust-Based Share Grant Program for Officers and Employees of Our U.S. Subsidiary | DAIICHI SANKYO COMPANY,LIMITED (4568) timely disclosure | Komori